Hela Cell Or Derivative Patents (Class 435/367)
-
Patent number: 12110504Abstract: Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.Type: GrantFiled: November 3, 2023Date of Patent: October 8, 2024Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States Government as represented by the Department of Veterans AffairsInventors: Zurab Siprashvili, Ngon T. Nguyen, M. Peter Marinkovich, Jean Tang, Alfred T. Lane, Paul A. Khavari
-
Patent number: 12105122Abstract: A voltage indicator includes a polypeptide sequence comprising a voltage-sensitive opsin domain and a capture protein domain arranged and disposed to capture a fluorescent dye ligand. When the fluorescent dye ligand is captured and the voltage indicator is bound to a cell membrane, an increase in voltage across the cell membrane causes an increase in fluorescent emission.Type: GrantFiled: January 27, 2023Date of Patent: October 1, 2024Assignee: HOWARD HUGHES MEDICAL INSTITUTEInventors: Eric R. Schreiter, Ahmed Abdelfattah
-
Patent number: 11999966Abstract: Nanostraws and to methods of utilizing them in order to deliver biologically relevant molecules such as DNA, RNA, proteins etc., into non-adherent cells such as immune cells, embryos, plant cells, bacteria, yeast etc. The methods described herein are repeatedly capable of delivering biologically relevant cargo into non-adherent cells, with high cell viability, dosage control, unaffected proliferation or cellular development, and with high efficiency. Among other uses, these new delivery methods will allow to scale pre-clinical cell reprogramming techniques to clinical applications.Type: GrantFiled: October 27, 2020Date of Patent: June 4, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karl Martin Hjort, Sergio Leal-Ortiz, Yuhong Cao, Chris Rehse, Andy Kah Ping Tay, Nicholas A. Melosh
-
Patent number: 11622998Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. An inflammatory composition comprising the above mentioned peptides is also described. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means, Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: GrantFiled: December 4, 2020Date of Patent: April 11, 2023Assignee: GemVax & KAEL Co., Ltd.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Patent number: 11278633Abstract: The invention, in some aspects, relates to dummy-fluorescent (DF) polypeptide molecules and their encoding nucleic acid molecules and use of such molecules in fusion proteins and their encoding nucleic acid molecules. Compositions of the invention may be delivered to cells and subjects and used in methods to modulate electrical activity of cells in which they are expressed, and for treatment of diseases and conditions in subjects.Type: GrantFiled: July 20, 2017Date of Patent: March 22, 2022Assignee: Massachusetts Institute of TechnologyInventors: Aimei Yang, Demian Park, Kiryl Piatkevich, Edward Boyden
-
Patent number: 9267099Abstract: Disclosed herein are capillary fabrication devices comprising living cells within a support medium. Culture of the cells produces viable lumenized capillary networks with natural or pre-determined geometries and ECM and basement membrane associated with the capillary networks. The capillary networks and the ECM and basement membrane detachable from the capillary networks are useful for tissue engineering applications.Type: GrantFiled: March 15, 2011Date of Patent: February 23, 2016Assignee: Indiana University Research and Technology CorporationInventors: James A. Glazier, Abdelkrim Alileche, Abbas Shrinifard, Dragos Amarie
-
Publication number: 20150139953Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.Type: ApplicationFiled: January 16, 2015Publication date: May 21, 2015Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
-
Publication number: 20150132277Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.Type: ApplicationFiled: October 9, 2014Publication date: May 14, 2015Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
-
Publication number: 20150132330Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.Type: ApplicationFiled: September 19, 2012Publication date: May 14, 2015Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
-
Publication number: 20150125893Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.Type: ApplicationFiled: November 6, 2014Publication date: May 7, 2015Inventors: Wolf B. Frommer, Cheng-Hsun Ho
-
Publication number: 20150126410Abstract: The invention relates in a first embodiment to a method for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region, wherein said adenoviruses are generated in a production cell, the method comprising the steps of: (a) expressing in said production cell an adenoviral pIX polypeptide from a nucleic acid sequence encoding said adenoviral pIX polypeptide under the control of (i) at least a minimal endogenous pIX promoter and a heterologous promoter; or (ii) a heterologous promoter; and (b) expressing in said production cell the elements necessary for the production and assembly of said adenoviruses from corresponding coding sequences, thereby increasing the yield of said adenoviruses generated in said production cell in comparison to the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region generated in said production cell in the absence of said nucleic acid sequence encoding said adenoviral pIX polypeptide.Type: ApplicationFiled: July 4, 2013Publication date: May 7, 2015Inventors: Christian Thirion, Zsolt Ruzsics
-
Publication number: 20150110836Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.Type: ApplicationFiled: May 21, 2013Publication date: April 23, 2015Inventor: Jacob E. Glanville
-
Publication number: 20150110825Abstract: The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.Type: ApplicationFiled: September 24, 2014Publication date: April 23, 2015Inventors: Ram SASISEKHARAN, Aditya RAGURAM, Vidya SUBRAMANIAN
-
Publication number: 20150111222Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.Type: ApplicationFiled: August 8, 2012Publication date: April 23, 2015Applicant: HOWARD hUGHES MEDICAL INSTITUTEInventors: Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
-
Publication number: 20150111233Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.Type: ApplicationFiled: October 17, 2014Publication date: April 23, 2015Inventors: Satoshi INOUYE, Junichi SATO
-
Publication number: 20150105315Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.Type: ApplicationFiled: October 21, 2014Publication date: April 16, 2015Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique IndustrielleInventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
-
Publication number: 20150104450Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.Type: ApplicationFiled: March 11, 2013Publication date: April 16, 2015Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
-
Publication number: 20150098956Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
-
Publication number: 20150087596Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.Type: ApplicationFiled: March 15, 2013Publication date: March 26, 2015Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
-
Publication number: 20150079127Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.Type: ApplicationFiled: December 2, 2014Publication date: March 19, 2015Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jos Kleuskens, Andreas Walter Claudius Rohwer
-
Publication number: 20150071858Abstract: The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.Type: ApplicationFiled: August 5, 2014Publication date: March 12, 2015Inventors: Per SVENNINGSSON, Paul GREENGARD
-
Publication number: 20150071883Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.Type: ApplicationFiled: September 10, 2014Publication date: March 12, 2015Inventor: Peter Cameron Colosi
-
Publication number: 20150072353Abstract: Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging.Type: ApplicationFiled: August 21, 2014Publication date: March 12, 2015Inventors: Jenny Jie Yang, Shen Tang
-
Publication number: 20150064716Abstract: The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use.Type: ApplicationFiled: November 17, 2014Publication date: March 5, 2015Inventors: Juan Saus, Fernando Revert
-
Publication number: 20150065560Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.Type: ApplicationFiled: April 1, 2014Publication date: March 5, 2015Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
-
Publication number: 20150064157Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Jonathan H. LeBowitz, John Maga
-
Publication number: 20150065436Abstract: The present invention relates to peptidomimetics that mimic helix ?B of the C-terminal transactivation domain of HIF-1?. Methods of using the peptidomimetics to, e.g., inhibit the HIF-1?-p300/CBP interaction, are also disclosed.Type: ApplicationFiled: September 3, 2014Publication date: March 5, 2015Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA, NEW YORK UNIVERSITYInventors: Paramjit S. ARORA, Brooke Bullock LAO, Laura K. HENCHEY, Nathaniel J. TRAASETH, Paul THOMSON, Swati KUSHAL, Bogdan Z. OLENYUK
-
Publication number: 20150057191Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
-
Publication number: 20150056271Abstract: Factor VIII variants and methods of use thereof are disclosed.Type: ApplicationFiled: August 25, 2014Publication date: February 26, 2015Inventors: Valder Arruda, Rodney Camire, Nicholas Iacobelli
-
Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
Patent number: 8961977Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.Type: GrantFiled: February 14, 2011Date of Patent: February 24, 2015Assignee: University of RochesterInventors: Stephen Dewhurst, Mark A. Sullivan -
Publication number: 20150050264Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.Type: ApplicationFiled: September 7, 2012Publication date: February 19, 2015Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Denis VIVIEN, Jerome PARCQ, Denis VIVIEN, Jerome PARCQ
-
Publication number: 20150044170Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.Type: ApplicationFiled: April 9, 2014Publication date: February 12, 2015Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Philip R. Johnson, JR., Kelly Reed Clark
-
Publication number: 20150037872Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.Type: ApplicationFiled: October 15, 2014Publication date: February 5, 2015Inventors: Erwin Ludo Roggen, Steffen Ernst, Allan Svendsen, Esben Peter Friis, Claus Von Der Osten
-
Publication number: 20150038675Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.Type: ApplicationFiled: February 12, 2013Publication date: February 5, 2015Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
-
Publication number: 20150031618Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.Type: ApplicationFiled: January 31, 2013Publication date: January 29, 2015Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
-
Publication number: 20150023960Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
-
Publication number: 20150023995Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.Type: ApplicationFiled: July 25, 2014Publication date: January 22, 2015Applicant: TAKEDA VACCINES, INC.Inventors: Charles RICHARDSON, Robert F. BARGATZE, Joel HAYNES, Bryan STEADMAN
-
Publication number: 20150004690Abstract: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.Type: ApplicationFiled: August 29, 2014Publication date: January 1, 2015Inventors: Corinne JOHN, Christian SCHAUB, Sabine WELLNITZ
-
Patent number: 8911776Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: GrantFiled: October 26, 2012Date of Patent: December 16, 2014Inventor: Claresa Levetan
-
Publication number: 20140356905Abstract: Compositions and methods for large-scale recombinant protein expression are disclosed.Type: ApplicationFiled: June 3, 2014Publication date: December 4, 2014Applicant: Rutgers, The State University of New JerseyInventors: John D. Altman, John C. Shires, Ankita Basant, Jillian Whidby, Joseph Marcotrigiano, Abdul G. Khan
-
Publication number: 20140356960Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.Type: ApplicationFiled: April 25, 2014Publication date: December 4, 2014Inventor: Imre Berger
-
Publication number: 20140356871Abstract: The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease.Type: ApplicationFiled: January 10, 2013Publication date: December 4, 2014Applicant: VIB VZWInventors: Albena Jordanova, Magdalena Zimon, Jonathan Baets, Peter De Jonghe
-
Publication number: 20140348817Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
-
Publication number: 20140343130Abstract: The present disclosure provides non-naturally occurring miR-196a-2 miRNAs and non-naturally occurring miR-204 miRNAs. The non-naturally occurring miRNAs of the disclosure have mature strand sequences distinct from their endogenous counterparts. The disclosure also provides methods of selecting mature strand sequences that function optimally in non-naturally occurring miR-196a-2 miRNAs. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway.Type: ApplicationFiled: August 7, 2014Publication date: November 20, 2014Inventors: Melissa Kelley, Amanda Birmingham, Jon Karpilow, Anastasia Khvorova, Kevin Sullivan
-
Publication number: 20140335568Abstract: The present disclosure relates to a nucleic acid assembly (NAA), comprising sensor domain and handle domain; an assembly interfaceable motif (AIM) sequence optionally along with intracellular targeting motif (ITM) sequence; and an AIM-NAA complex. It also relates to a vector comprising assembly interfaceable motif sequence optionally along with intracellular targeting motif sequence and a cell comprising the vector. Further, the instant disclosure also provides a method to obtain the nucleic acid assembly, method of intracellular targeting and kit thereof.Type: ApplicationFiled: October 11, 2012Publication date: November 13, 2014Applicant: NATIONAL CENTRE FOR BIOLOGICAL SCIENCESInventors: Yamuna Krishnan, Souvik Modi
-
Publication number: 20140335539Abstract: A method for detecting an interaction between a first protein and a second protein comprises the steps of: expressing in a cell a first fusion protein comprising the first protein and an association-inducing protein, and a second fusion protein comprising the second protein and a fluorescent protein having a multimerization ability; detecting a fluorescent focus formed by an association between the first fusion protein and the second fusion protein in the cell; and determining an interaction between the first protein and the second protein according to the detection of the fluorescent focus.Type: ApplicationFiled: December 5, 2012Publication date: November 13, 2014Applicant: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.Inventors: Taku Watanabe, Tatsuya Seki, Aki Fujioka
-
Publication number: 20140335053Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.Type: ApplicationFiled: May 22, 2014Publication date: November 13, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
-
Publication number: 20140328875Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.Type: ApplicationFiled: December 17, 2013Publication date: November 6, 2014Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
-
Publication number: 20140323348Abstract: Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Hiroaki Matsunami, Yue Jiang, Ming-Shan Chien
-
Publication number: 20140323401Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.Type: ApplicationFiled: April 8, 2014Publication date: October 30, 2014Applicant: Araim Pharmaceuticals, Inc.Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN